Evotec
Frank Selbeck is a seasoned finance and risk management professional with extensive experience in the pharmaceutical and financial services industries. Currently serving as the Senior Vice President and Head of Global Tax, Risk & Control at Evotec since August 2020, Frank reports directly to the group CFO of Evotec SE, a leading drug discovery and development company based in Germany. Prior roles include Senior Vice President at Evotec overseeing Global Risk Governance, Control (SOX Compliance), and Insurance, as well as Senior Vice President of Global Risk Management at Mazars in Germany. Frank's background encompasses leadership positions at Bertelsmann SE & Co. KGaA and Salomon Invest Group, alongside a managerial role in audit at EY, focusing on statutory and compliance audits as well as risk management systems. Frank holds a Diplom Kaufmann degree in Business Economics from Fontys University of Applied Sciences.
This person is not in any teams
This person is not in any offices
Evotec
5 followers
Evotec AG is a drug discovery and development company. The Company operates through two segments. The EVT Execute segment provides standalone drug discover services on a typical fee-for-service basis or integrated drug discovery collaborations on partners' target through a range of commercial structures, including research fees, milestones and/or royalties. The EVT Innovate segment develops drug discovery programs and assets, both internally or through academic collaborations. The Company seeks to partner these into collaborations in return for upfront payments, ongoing research payments. It consists of all partnerships derived from its internally developed assets and platforms and its participations in certain companies. It includes clinical initiations and progress of clinical pipeline within partnerships; expansion of academic BRIDGE network; research and development (R&D) progress with CureX/Target X initiatives, and focuses on induced pluripotent stem cells (iPSC) platform.